Today’s Research Reports on Trending Tickers: PTC Therapeutics and Valeant Pharmaceuticals

The Dow Jones Industrial Average and the S&P 500 Index edged higher Thursday as investors continued to digest details of the GOP’s tax reform plan and data showed the U.S. economy accelerated in the second quarter. The Dow Jones gained 0.16 percent to close at 22,376.60, while the S&P 500 Index increased 0.12 percent to close at 2,509.96. The Nasdaq Composite Index rallied late to close flat for the day at 6,453.45. On Thursday, the Commerce Department reported gross domestic product grew at an annual rate of 3.1 percent in the April-June quarter, up from its previous estimate of 3.0 percent last month.

“The destruction caused by Hurricanes Harvey and Irma and the resulting disruption … are expected to be a drag on third-quarter growth,” said Jim Baird, chief investment officer at Plante Moran Financial Advisors in Kalamazoo, Michigan, according to Reuters. “Nonetheless, the economy remains on track.”

RDI Initiates Coverage on:

PTC Therapeutics, Inc.

Valeant Pharmaceuticals Intl Inc.

PTC Therapeutics Inc.’s stock had no change Thursday, to close the day at $17.46. The stock recorded a trading volume of 318,170 shares, which was below its three months average volume of 651,323 shares. In the last year PTC Therapeutics Inc.’s shares have traded in a range of 4.03 – 22.00. The share price has gained 333.25% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $19.53 is greater than its 200-day moving average of $15.36. Shares of PTC Therapeutics have gained approximately 60.04 percent year-to-date.

Access RDI’s PTC Therapeutics, Inc. Research Report at:

On Thursday, shares in Valeant Pharmaceuticals Intl Inc. recorded a trading volume of 20,569,458 shares, which was above the three months average volume of 16,585,000 shares. The stock ended the day 4.38% lower at 13.76. The share price has gained 65.58% from its 52 week low with a 52 week trading range of 8.31 – 27.84.The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $14.22 is greater than its 200-day moving average of $13.18. Shares of Valeant Pharmaceuticals have fallen approximately 5.23 percent year-to-date.

Access RDI’s Valeant Pharmaceuticals Intl Inc. Research Report at:

Our Actionable Research on PTC Therapeutics, Inc. (NASDAQ:PTCT) and Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.